Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CS-747S Phase III Non-inferiority Study vs Clopidogrel in Non-cardioembolic Stroke
jRCT2080221542Phase 3Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Aug 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of prasugrel in Noncardioembolic stroke (NCES), myocardial infarction (MI), cerebrovascular disease and 1 more (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Composite of ischemic stroke, myocardial infarction, and other vascular death. Started Aug 2011; status: completed.
02
Drugs
prasugrel
03
Conditions
Noncardioembolic stroke (NCES)myocardial infarction (MI)cerebrovascular diseasecardiac morbidity
Beyond the preview
Go deeper on jRCT2080221542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221542.